266 related articles for article (PubMed ID: 38540261)
1. The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma.
Gergely L; Udvardy M; Illes A
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540261
[TBL] [Abstract][Full Text] [Related]
2. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.
Castillo JJ; Beltran BE; Miranda RN; Young KH; Chavez JC; Sotomayor EM
Am J Hematol; 2018 Jul; 93(7):953-962. PubMed ID: 29984868
[TBL] [Abstract][Full Text] [Related]
3. EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda.
Tumwine LK; Orem J; Kerchan P; Byarugaba W; Pileri SA
Infect Agent Cancer; 2010 Jun; 5():12. PubMed ID: 20591151
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Uccini S; Al-Jadiry MF; Scarpino S; Ferraro D; Alsaadawi AR; Al-Darraji AF; Moleti ML; Testi AM; Al-Hadad SA; Ruco L
Hum Pathol; 2015 May; 46(5):716-24. PubMed ID: 25704629
[TBL] [Abstract][Full Text] [Related]
5. Diffuse large B-cell lymphoma in a South African cohort with a high HIV prevalence: an analysis by cell-of-origin, Epstein-Barr virus infection and survival.
Cassim S; Antel K; Chetty DR; Oosthuizen J; Opie J; Mohamed Z; Verburgh E
Pathology; 2020 Jun; 52(4):453-459. PubMed ID: 32305135
[TBL] [Abstract][Full Text] [Related]
6. TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
Cho J; Kim E; Yoon SE; Kim SJ; Kim WS
Cancer; 2023 May; 129(10):1502-1512. PubMed ID: 36812290
[TBL] [Abstract][Full Text] [Related]
7. Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma.
Chabay P
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072731
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-positive diffuse large B-cell lymphoma association is not only restricted to elderly patients.
Cohen M; Narbaitz M; Metrebian F; De Matteo E; Preciado MV; Chabay PA
Int J Cancer; 2014 Dec; 135(12):2816-24. PubMed ID: 24789501
[TBL] [Abstract][Full Text] [Related]
9. Presence of Epstein-Barr virus (EBV) antigens detected by sensitive methods has no influence on local immune environment in diffuse large B cell lymphoma.
Mangiaterra T; Alonso-Alonso R; Rabinovich A; De Dios Soler M; Galluzzo L; Soria M; Colli S; De Matteo E; Rodriguez Pinilla SM; Chabay P
Cancer Immunol Immunother; 2024 Jan; 73(2):29. PubMed ID: 38280007
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus (EBV) provides survival factors to EBV
Wu L; Ehlin-Henriksson B; Zhou X; Zhu H; Ernberg I; Kis LL; Klein G
Immunology; 2017 Dec; 152(4):562-573. PubMed ID: 28699226
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analysis of neoplastic PD-L1-positive EBV
Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
[TBL] [Abstract][Full Text] [Related]
12. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management.
Malpica L; Marques-Piubelli ML; Beltran BE; Chavez JC; Miranda RN; Castillo JJ
Am J Hematol; 2022 Jul; 97(7):951-965. PubMed ID: 35472248
[TBL] [Abstract][Full Text] [Related]
13. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Shimada S; Eladl AE; Elsayed AA; Daroontum T; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
Pathol Int; 2020 Aug; 70(8):481-492. PubMed ID: 32367595
[TBL] [Abstract][Full Text] [Related]
14. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
Witte HM; Merz H; Biersack H; Bernard V; Riecke A; Gebauer J; Lehnert H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2020 Apr; 189(2):257-268. PubMed ID: 31958882
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
[TBL] [Abstract][Full Text] [Related]
16. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
17. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.
Beltran BE; Castro D; Paredes S; Miranda RN; Castillo JJ
Am J Hematol; 2020 Apr; 95(4):435-445. PubMed ID: 32072672
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, in the Oral Cavity.
Costa SFDS; Silva AMB; Amaral-Silva GK; Pontes HAR; Pontes FSC; Fonseca FP; Almeida OP
J Craniofac Surg; 2019; 30(3):e259-e262. PubMed ID: 31048622
[TBL] [Abstract][Full Text] [Related]
19. Plasma Epstein-Barr virus and Hepatitis B virus in non-Hodgkin lymphomas: Two lymphotropic, potentially oncogenic, latently occurring DNA viruses.
Sinha M; Rao CR; Premalata CS; Shafiulla M; Lakshmaiah KC; Jacob LA; Babu GK; Viveka BK; Appaji L; Subramanyam JR
Indian J Med Paediatr Oncol; 2016; 37(3):146-51. PubMed ID: 27688607
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
